about
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.PEGylation and its impact on the design of new protein-based medicines.Synthesis and antiviral properties of novel tetracyclic nucleoside inhibitors of hepatitis C NS5B polymerase.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging therapies for hepatitis C virus.
@en
Emerging therapies for hepatitis C virus.
@nl
type
label
Emerging therapies for hepatitis C virus.
@en
Emerging therapies for hepatitis C virus.
@nl
prefLabel
Emerging therapies for hepatitis C virus.
@en
Emerging therapies for hepatitis C virus.
@nl
P2860
P1476
Emerging therapies for hepatitis C virus.
@en
P2093
Aybike Birerdinc
Zobair M Younossi
P2860
P304
P356
10.1517/14728214.2010.502527
P407
P577
2010-07-15T00:00:00Z